Skip to content

Annual MRI Versus Biannual US for Surveillance of Hepatocellular Carcinoma in Liver Cirrhosis

Annual MRI Versus Biannual US for Surveillance of Hepatocellular Carcinoma in Liver Cirrhosis (MAGNUS-HCC)

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
CRIS
Registry ID
KCT0001739
Enrollment
211
Registered
2015-12-23
Start date
2015-10-12
Completion date
Unknown
Last updated
2019-03-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

None listed

Sponsors

The Catholic University of Korea
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Male or female subject between 20 and 70 years of age at the enrollment Has chronic liver disease Fulfill below conditions A and B A.The evidence of cirrhosis of any etiology within 12 months prior to screening Definition of cirrhosis by any of following methods 1) Histologically by liver biopsy; 2) Non-histologically by evidence of portal hypertension in the presence of chronic liver disease; - Evidence of portal hypertension, including any of followings; >The identification of splenomegaly on ultrasonography, CT, or MRI examinations with typical features of cirrhosis >The identification of esophageal or gastric varices on endoscopic examination B. Risk Index more than 2.33 ; Risk Index = 1.65 (if PT% is <=75%) + 1.41 (if the age is 50 years or older) + 0.92 (if the platelet count is <=100x10(3)/mm3) + 0.74 (if the presence of HCV is positive).

Exclusion criteria

Exclusion criteria: Presence of liver cancer or other malignancy No liver cirrhosis pregnant or breast-feeding

Design outcomes

Primary

MeasureTime frame
Sensitivity

Secondary

MeasureTime frame
False referral rate

Countries

Korea, Republic of

Contacts

Public ContactJoon-Il Choi

The Catholic University of Korea

dumkycji@gmail.com+82-2-2258-1431

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Mar 8, 2026